Slide 1: FY26 Results
FY26 RESULTS Jason Martinez - Managing Director & CEO Craig White – CFO 25 August 2026
Slide 2: FY26 Results Overview – Key Highlights
FY26 RESULTS OVERVIEW – KEY HIGHLIGHTS Group Group 1 Strong revenue growth of 25.6% to �788.7m AUD $m FY26 vs FY25 Revenue 788.7 25.6% (1) 2 Improved operating EBITDA margin of 20.9% (up 80bps vs FY25), in line with guidance Operating EBITDA 164.8 30.3% Operating EBITDA margin 20.9% 0.8% Margin grow
Slide 3: Strategic Overview – Key Progress Update
STRATEGIC OVERVIEW – KEY PROGRESS UPDATE Capitol merger LFL organic growth Greenfield and inorganic growth Integration largely completed - annual Continued evaluation and implementation synergies of �14m+ significantly exceed Ongoing focus on driving organic growth of incremental greenfield an
Slide 4: IDX Operational Platform
IDX OPERATIONAL PLATFORM IDX operational platform Enhanced • High quality network of 142 sites across Australia and New operational Zealand with 468 radiologists(1) and ~3,000 staff scale and • GP and specialist referral network in metro and regional 142 Total IDX sites network areas IDXt coverage S
Slide 5: Continuing to Deliver on Our Values in FY26
CONTINUING TO DELIVER ON OUR VALUES IN FY26 • Excellent average patient • 468 employed or • ~3,000 employees • Annual ongoing merger • Continuing focus on • Continuing to broaden NPS of +81(1) contracted reporting synergies achieved from delivering our ESG strategy referrer base in NZ to radiologist
Slide 6: Financial Performance
FINANCIAL PERFORMANCE FY26 Investor Presentation 6
Slide 7: FY26 Financial Results – Overview
FY26 FINANCIAL RESULTS – OVERVIEW Group Group(1) Group Group AUD $m FY26 FY25 Var. ($) Var. (%) Revenue 788.7 628.0 160.7 25.6% (2) Operating EBITDA 164.8 126.5 38.3 30.3% Operating EBITDA margin 20.9% 20.1% 0.8% Operating EBITA(2) 97.1 70.0 27.1 38.8% Operating EBITA margin 12.3% 11.1% 1.2% Operati
Slide 8: FY26 Financial Results - Pro Forma Profit & Loss
FY26 FINANCIAL RESULTS - PRO FORMA PROFIT & LOSS Group IDX Capitol(1) Pro Forma(2) Key comments: AUD $m FY26 FY25 FY25 FY25 Var. ($) Var. (%) FY26 Operating EBITDA margin of 20.9%, 70bps Revenue(3) • 788.7 501.2 245.6 746.8 41.9 5.6% stronger than FY25 pro forma Adjusted Operating EBITDA margin of 2
Slide 9: FY26 Financial Results – Revenue
FY26 FINANCIAL RESULTS – REVENUE Group IDX Capitol(1) Pro Forma(2) AUD $m FY26 FY25 FY25 FY25 Var. ($) Var. (%) Revenue(3) 788.7 501.2 245.6 746.8 41.9 5.6% Key comments: • Solid Group revenue growth driven by growth in patient volumes, Medicare indexation and continued favourable mix impact, being
Slide 10: FY26 Financial Results – Operating Expenditure
FY26 FINANCIAL RESULTS – OPERATING EXPENDITURE % of Revenue (1) (2) Group IDX Capitol Pro forma Group Pro forma(2) AUD $m FY26 FY25 FY25 FY25 Var. ($) Var. (%) FY26 FY25 Consumables 35.9 24.0 7.5 31.5 4.4 14.2% 4.6% 4.2% Labour(3) 493.3 318.0 149.0 467.0 26.3 5.6% 62.5% 62.9% Equipment 23.8 15.1 7.4
Slide 11: FY26 Financial Results - Cash Flow / Cash Conversion
FY26 FINANCIAL RESULTS - CASH FLOW / CASH CONVERSION Group Group(1) AUD $m FY26 FY25 Var. ($) Var. (%) Operating EBITDA 164.8 126.5 38.3 30.3% Non-cash items in EBITDA 0.4 1.5 (1.1) (76.0%) Changes in working capital (9.3) (0.2) (9.1) n.m. Cash payments on lease principal element (20.7) (18.4) (2.3)
Slide 12: Capital Expenditure
CAPITAL EXPENDITURE Capex investment of �49.8m (being mid-point of guidance of �45.0-55.0m) aligned with IDX’s strategy, both enhancing and expanding the equipment fleet for the benefit of patients FY26 replacement capex of �28.8m Replacement capex reflects capital sensitivity requirements, site ref
Slide 13: Balance Sheet
BALANCE SHEET Group Group Group Key comments: AUD �m 30 Jun 2026 30 Jun 2025 30 Jun 2024 • FY26 net debt of $298.9m(1) (FY25: $298.0m), being 2.3x(2) EBITDA prior to non-operating Cash and cash equivalents 51.3 52.1 42.4 transactions at 30 June 2026 (FY25: 2.6x(2)) on a pre-AASB 16 basis, projected
Slide 14: Industry and Regulatory Update
INDUSTRY AND REGULATORY UPDATE FY26 Investor Presentation 14
Slide 15: Diagnostic Industry Fundamentals
DIAGNOSTIC INDUSTRY FUNDAMENTALS IDX well positioned to improve access and benefits for patients and capitalise on positive industry fundamentals Ageing population and earlier detection of disease driving increasing demand for diagnostic services. Medicare DI benefits and services growing co
Slide 16: Industry Growth
INDUSTRY GROWTH Medicare DI benefits and services growing consistently above long-term growth averages since September 2023, with divergence between benefits and services reflecting stronger growth in higher acuity modalities 15.0% Commentary Industry growth rates, on a 12–month rolling basis, conti
Slide 17: FY27 Strategy, Priorities and Outlook
FY27 STRATEGY, PRIORITIES AND OUTLOOK FY26 Investor Presentation 17
Slide 18: Strategic Focus in FY2027 and Beyond
STRATEGIC FOCUS IN FY2027 AND BEYOND Building from strong FY26 delivery: disciplined growth, productivity and long-term value creation Core Growth Network People Transformation & Optimisation Expansion & Culture & Innovation Execute within the platform Disciplined, selective growth Capacity, capabil
Slide 19: FY27 Priorities
FY27 PRIORITIES Clear commitments, measures and reporting cadence to support execution discipline 1 Revenue Management 2 Margin Improvement 3 Capital Management Commitment: Commitment: Commitment: 1 Revenue optimisation: 1 Remuneration focus: 1 New Zealand strategic review • Volume • Productivity 2
Slide 20: Questions
QUESTIONS FY26 Investor Presentation 20
Slide 21: Appendices
APPENDICES FY26 Investor Presentation 21
Slide 22: Group Overview
GROUP OVERVIEW Geographic Market Victoria New South Wales Queensland Western Australia Tasmania South Australia New Zealand Metro and outer Western Sunshine Coast, Melbourne, Geelong, Ballarat, Rockhampton, Metro Perth, Albury, Lavington, Core markets Warrnambool, Mildura, Gladstone, Gold South West
Slide 23: Reconciliation of Operating to Reported EBITDA and Operating to Statutory NPAT
RECONCILIATION OF OPERATING TO REPORTED EBITDA AND OPERATING TO STATUTORY NPAT Group Group(1) Group Group AUD $m FY26 FY25 Var. ($) Var. (%) Operating NPAT 47.4 31.6 15.8 50.1% Non operating transactions, net of tax Remeasurement of contingent consideration liabilities - 5.5 Transaction, restructuri
Slide 24: Supplementary Information – Items Below EBITDA
SUPPLEMENTARY INFORMATION – ITEMS BELOW EBITDA Group IDX Capitol(1) Pro forma(2)(3) AUD $m FY26 FY25 FY25 FY25 Var. ($) Var. (%) Comments Operating costs below EBITDA (excl. tax) Depreciation of property, plant & equipment 39.8 27.7 12.0 39.7 0.1 0.3% Depreciation charge on PP&E and capitalised soft
Slide 25: Disclaimer
DISCLAIMER 1. Some of the information contained in this 3. Past performance of IDX cannot be relied 5. Reliance should not be placed on the presentation contains “forward-looking upon as an indicator of (and provides no information or opinions contained in this statements” which may not directly or